胃がん診断の世界市場：市場規模・シェア・動向分析 (製品別・疾患の種類別・最終用途別・地域別)、セグメント別予測 (2025年～2033年)

胃がん診断市場の概要

世界の胃がん診断市場は、2024年に11億8,000万米ドルと推計され、2033年には22億2,000万米ドルに達すると予測され、2025年から2033年までのCAGRは7.43%で成長します。胃がんの罹患率の上昇、早期発見とスクリーニング・プログラムの重視の高まり、個別化医薬品に対する需要の高まりが市場の成長を牽引しています。

胃がんは世界で5番目に多いがんであり、その罹患率の上昇が高度な診断ツールの需要を押し上げ、早期発見と患者の転帰改善の緊急の必要性を浮き彫りにしています。米国国立がん研究所（NIH）によると、2025年には新たに約30,300人の胃がん患者が発生し、約10,780人が死亡すると予測されています。

ヘリコバクター・ピロリ菌の感染、喫煙、高塩分食、加齢などの要因が、疾病負担を増加させています。胃がんの死亡率は高齢になるほど上昇します。2019年と2023年の年齢調整死亡率は、男女ともに年間10万人当たり2.7人です。下図は、2019年から2022年までの胃がんの年齢層別新規症例数割合（％）を示したものです。

胃がんは、世界的にがん関連死亡の主な原因の1つであることから、早期で正確な診断ツールに対する需要が高まっています。ヘルスケアシステムは、検診プログラムと早期発見に重点を置いており、これが内視鏡検査、生検、画像技術、分子診断の必要性を高め、従来型と先進型の両方の診断ソリューションの市場を大幅に拡大しています。

市場成長のもう一つの要因は、高リスク集団の胃がんをより早期に、より治療可能な段階で発見するために、世界中の政府やヘルスケア機関が実施している検診プログラムの拡大です。例えば2025年4月、米国国立衛生研究所（NIH）は、研究者、臨床医、コンピュータ科学者からなる全国チームを率いて米国における胃がん検診の実現可能性を評価するため、5年間で260万米ドルを研究者に授与しました。日本や韓国のような国では、内視鏡検査を含む全国的な検診イニシアチブを確立しており、死亡率の減少に有効であることが証明されています。同様のプログラムが他の地域にも拡大するにつれ、正確で効率的な診断ツールの必要性が高まっています。予防腫瘍学と早期発見を目指すこの動きは、特に公的医療制度が長期的な治療費の削減を目指す中、胃がん診断業界の強力な推進力となっています。

個別化医療へのシフトは胃がん診断業界に大きな影響を与えています。バイオマーカーに基づく検査とゲノム・プロファイリングにより、臨床医は個々の患者プロファイルに合わせた治療を行うことができ、治療成績が向上します。この精密なアプローチは、次世代シーケンシング（NGS）、免疫組織化学、コンパニオン診断薬などの高度な診断ツールに依存しています。標的治療が普及するにつれ、胃がんにおけるHER2、PD-L1、MSI、その他のバイオマーカーを同定する分子診断の必要性が高まっています。個別化医療は生存率を向上させ、治療の費用対効果を高めるため、ヘルスケアプロバイダーと支払者の双方に、より高度な診断プラットフォームの導入を促しています。例えば、転移性胆道がんでは、若年者の方が高齢者よりも予後が良好である傾向がありますが、これは彼らの腫瘍には個別化治療の候補となる実用的な遺伝子変化が含まれている可能性が高いからです。

バイオマーカーは、がん開発に関連する分子的・遺伝的変化を早期に検出することができ、これは患者の予後を改善するために極めて重要です。バイオマーカー、特に血液やその他の体液に含まれるバイオマーカーは、非侵襲的あるいは低侵襲的な選択肢を提供し、内視鏡検査や生検に比べて患者の不快感を軽減します。また、病気の進行や治療効果をリアルタイムでモニターすることができ、個別化医療を促進します。さらに、バイオマーカーは、低解像度やオペレーター依存といった画像診断の限界を克服し、より高い感度と特異性で良性病変と悪性病変を区別するのに役立ちます。そこで、胃がん診断におけるバイオマーカーの新たな動向を以下に示します。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 胃がん診断市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 胃がん診断市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 胃がん診断市場：製品別の推定・動向分析

• 市場シェア：製品別（2024年・2033年）
• セグメントダッシュボード
• 胃がん診断市場：変動分析、製品別
• 胃がん診断の市場規模と動向分析：製品別（2021～2033年）
• 胃がん診断市場：収益の推計・予測（2021年～2033年）
• 試薬・消耗品
• 機器

第5章 胃がん診断市場：疾患の種類別の推定・動向分析

• 市場シェア：疾患の種類別（2024年・2033年）
• セグメントダッシュボード
• 胃がん診断市場：変動分析、疾患の種類別
• 市場規模の予測と動向分析（2021～2033年）
• 腺がん
• 胃リンパ腫
• その他

第6章 胃がん診断市場：最終用途別の推定・動向分析

• 市場シェア：最終用途別（2024年・2033年）
• セグメントダッシュボード
• 胃がん診断市場：変動分析、最終用途別
• 市場規模の予測と動向分析（2021～2033年）
• 病院
• 診断検査室
• 診断画像

第7章 胃がん診断市場：地域別の推定・動向分析

• 市場シェア：地域別（2024年・2033年）
• 市場ダッシュボード：地域別
• 世界市場のスナップショット：地域別
• 市場規模の予測と動向分析（2021～2033年）
• 北米
  • 北米：SWOT分析
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州：SWOT分析
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • アジア太平洋地域：SWOT分析
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカ：SWOT分析
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • MEA：SWOT分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 最近の動向と影響分析：主要企業別
• 企業/競合の分類
• ベンダー情勢
  • 主要な販売代理店・チャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析（2024年）
  • MiRXES Pte Ltd.
  • Agilent Technologies Inc
  • Endofotonics Pte Ltd
  • Bio-Rad Laboratories, Inc
  • Hipro Biotechnology Co., Ltd
  • Exact Sciences Corporation
  • QIAGEN
  • Fulgent Genetics.
  • F. Hoffmann-La Roche Ltd
  • Abbott

List of Tables

• Table 1 List of abbreviations
• Table 2 North America Gastric Cancer Diagnostics market, by region, 2021 - 2033 (USD Million)
• Table 3 North America Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 4 North America Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 5 North America Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 6 U.S Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 7 U.S Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 8 U.S Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 9 Canada Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 10 Canada Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 11 Canada Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 12 Mexico Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 13 Mexico Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 14 Mexico Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 15 Europe Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 16 Europe Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 17 Europe Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 18 UK Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 19 UK Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 20 UK Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 21 Germany Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 22 Germany Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 23 Germany Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 24 France Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 25 France Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 26 France Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 27 Italy Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 28 Italy Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 29 Italy Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 30 Spain Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 31 Spain Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 32 Spain Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 33 Denmark Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 34 Denmark Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 35 Denmark Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 36 Sweden Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 37 Sweden Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 38 Sweden Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 39 Norway Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 40 Norway Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 41 Norway Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 42 Asia Pacific Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 43 Asia Pacific Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 44 Asia Pacific Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 45 Japan Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 46 Japan Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 47 Japan Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 48 China Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 49 China Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 50 China Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 51 India Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 52 India Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 53 India Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 54 Australia Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 55 Australia Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 56 Australia Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 57 South Korea Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 58 South Korea Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 59 South Korea Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 60 Thailand Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 61 Thailand Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 62 Thailand Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 63 Latin America Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 64 Latin America Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 65 Latin America Gastric Cancer Diagnostics market, by end use 2021 - 2033 (USD Million)
• Table 66 Brazil Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 67 Brazil Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 68 Brazil Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 69 Argentina Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 70 Argentina Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 71 Argentina Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 72 MEA Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 73 MEA Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 74 MEA Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 75 South Africa Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 76 South Africa Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 77 South Africa Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 78 Saudi Arabia Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 79 Saudi Arabia Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 80 Saudi Arabia Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 81 UAE Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 82 UAE Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 83 UAE Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
• Table 84 Kuwait Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
• Table 85 Kuwait Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
• Table 86 Kuwait Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Gastric Cancer Diagnostics market: market outlook
• Fig. 14 Gastric Cancer Diagnostics Competitive Insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Gastric Cancer Diagnostics Market Driver Impact
• Fig. 20 Gastric Cancer Diagnostics Market Restraint Impact
• Fig. 21 Gastric Cancer Diagnostics Market Strategic Initiatives Analysis
• Fig. 22 Gastric Cancer Diagnostics market: Product movement analysis
• Fig. 23 Gastric Cancer Diagnostics market: Product outlook and key takeaways
• Fig. 24 Reagents & consumables market estimates and forecasts, 2021 - 2033
• Fig. 25 Instruments market estimates and forecasts,2021 - 2033
• Fig. 26 Gastric Cancer Diagnostics Market: Disease Type Movement Analysis
• Fig. 27 Gastric Cancer Diagnostics market: Disease type outlook and key takeaways
• Fig. 28 Adenocarcinoma market estimates and forecasts, 2021 - 2033
• Fig. 29 Gastric lymphoma market estimates and forecasts, 2021 - 2033
• Fig. 30 Other market estimates and forecasts, 2021 - 2033
• Fig. 31 Gastric Cancer Diagnostics Market: End use movement analysis
• Fig. 32 Gastric Cancer Diagnostics market: End use outlook and key takeaways
• Fig. 33 Hospitals market estimates and forecasts, 2021 - 2033
• Fig. 34 Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
• Fig. 35 Diagnostic Imaging market estimates and forecasts, 2021 - 2033
• Fig. 36 Global Gastric Cancer Diagnostics market: Regional movement analysis
• Fig. 37 Global Gastric Cancer Diagnostics market: Regional outlook and key takeaways
• Fig. 38 Global Gastric Cancer Diagnostics market share and leading players
• Fig. 39 North America market share and leading players
• Fig. 40 Europe market share and leading players
• Fig. 41 Asia Pacific market share and leading players
• Fig. 42 Latin America market share and leading players
• Fig. 43 Middle East & Africa market share and leading players
• Fig. 44 North America, by country
• Fig. 45 North America
• Fig. 46 North America market estimates and forecasts, 2021 - 2033
• Fig. 47 U.S.
• Fig. 48 U.S. market estimates and forecasts, 2021 - 2033
• Fig. 49 Canada
• Fig. 50 Canada market estimates and forecasts, 2021 - 2033
• Fig. 51 Mexico
• Fig. 52 Mexico market estimates and forecasts, 2021 - 2033
• Fig. 53 Europe
• Fig. 54 Europe market estimates and forecasts, 2021 - 2033
• Fig. 55 UK
• Fig. 56 UK market estimates and forecasts, 2021 - 2033
• Fig. 57 Germany
• Fig. 58 Germany market estimates and forecasts, 2021 - 2033
• Fig. 59 France
• Fig. 60 France market estimates and forecasts, 2021 - 2033
• Fig. 61 Italy
• Fig. 62 Italy market estimates and forecasts, 2021 - 2033
• Fig. 63 Spain
• Fig. 64 Spain market estimates and forecasts, 2021 - 2033
• Fig. 65 Denmark
• Fig. 66 Denmark market estimates and forecasts, 2021 - 2033
• Fig. 67 Sweden
• Fig. 68 Sweden market estimates and forecasts, 2021 - 2033
• Fig. 69 Norway
• Fig. 70 Norway market estimates and forecasts, 2021 - 2033
• Fig. 71 Asia Pacific
• Fig. 72 Asia Pacific market estimates and forecasts, 2021 - 2033
• Fig. 73 China
• Fig. 74 China market estimates and forecasts, 2021 - 2033
• Fig. 75 Japan
• Fig. 76 Japan market estimates and forecasts, 2021 - 2033
• Fig. 77 India
• Fig. 78 India market estimates and forecasts, 2021 - 2033
• Fig. 79 Thailand
• Fig. 80 Thailand market estimates and forecasts, 2021 - 2033
• Fig. 81 South Korea
• Fig. 82 South Korea market estimates and forecasts, 2021 - 2033
• Fig. 83 Australia
• Fig. 84 Australia market estimates and forecasts, 2021 - 2033
• Fig. 85 Latin America
• Fig. 86 Latin America market estimates and forecasts, 2021 - 2033
• Fig. 87 Brazil
• Fig. 88 Brazil market estimates and forecasts, 2021 - 2033
• Fig. 89 Argentina
• Fig. 90 Argentina market estimates and forecasts, 2021 - 2033
• Fig. 91 Middle East and Africa
• Fig. 92 Middle East and Africa market estimates and forecasts, 2021 - 2033
• Fig. 93 South Africa
• Fig. 94 South Africa market estimates and forecasts, 2021 - 2033
• Fig. 95 Saudi Arabia
• Fig. 96 Saudi Arabia market estimates and forecasts, 2021 - 2033
• Fig. 97 UAE
• Fig. 98 UAE market estimates and forecasts, 2021 - 2033
• Fig. 99 Kuwait
• Fig. 100 Kuwait market estimates and forecasts, 2021 - 2033
• Fig. 101 Market share of key market players- Gastric Cancer Diagnostics market

Gastric Cancer Diagnostics Market Summary

The global gastric cancer diagnostics market was estimated at USD 1.18 billion in 2024 and is projected to reach USD 2.22 billion by 2033, growing at a CAGR of 7.43% from 2025 to 2033. The market is growing, driven by the rising incidence of gastric cancer, growing emphasis on early detection and screening programs, and escalating demand for personalized medicines.

Gastric cancer ranks as the 5th most common cancer worldwide, and its rising incidence drives the demand for advanced diagnostic tools, highlighting the urgent need for early detection and improved patient outcomes. According to the National Cancer Institute (NIH), in 2025, it is projected that there will be approximately 30,300 new stomach cancer cases, with about 10,780 deaths expected from the disease

Some of the factors, such as Helicobacter pylori infection, smoking, high-salt diets, and aging, are contributing to a higher disease burden. The mortality rate for gastric cancer rises as people get older. In 2019 and 2023, the age-adjusted death rate for both men and women was 2.7 per 100,000 individuals annually. The chart below illustrates the percentage of new cases (%) by age group of gastric cancer for the period 2019-2022

Gastric cancer, being one of the leading causes of cancer-related deaths worldwide, has led to a rising demand for its early, accurate diagnostic tools. Healthcare systems are placing greater emphasis on screening programs and early detection, which drives the need for endoscopy, biopsy, imaging technologies, and molecular diagnostics, significantly expanding the market for both conventional and advanced diagnostic solutions.

Another factor for market growth is growing screening programs that the governments and healthcare organizations worldwide are implementing to detect gastric cancer in high-risk populations at earlier, more treatable stages. For instance in April, 2025, National Institutes of Health (NIH) has awarded a researcher USD 2.6 million over five years to lead a national team of researchers, clinicians, and computer scientists in evaluating the feasibility of gastric cancer screening in the U.S. Early detection significantly improves survival rates, prompting increased investments in diagnostic infrastructure. Countries like Japan and South Korea have established nationwide screening initiatives that include endoscopic examinations, which have proven effective in reducing mortality. As similar programs expand to other regions, the need for accurate and efficient diagnostic tools grows. This push toward preventive oncology and early-stage detection is a powerful driver of the gastric cancer diagnostics industry, especially as public health systems seek to reduce long-term treatment costs.

The shift toward personalized medicine is significantly influencing the gastric cancer diagnostics industry. Biomarker-based tests and genomic profiling allow clinicians to tailor treatments to individual patient profiles, improving therapeutic outcomes. This precision approach relies on advanced diagnostic tools such as next-generation sequencing (NGS), immunohistochemistry, and companion diagnostics. As targeted therapies become more prevalent, the need for molecular diagnostics to identify HER2, PD-L1, MSI, and other biomarkers in gastric cancer grows. Personalized medicine improves survival and enhances the cost-effectiveness of care, encouraging both healthcare providers and payers to adopt more advanced diagnostic platforms. For example, in metastatic biliary tract cancers, younger individuals tended to have a better prognosis than older patients, because their tumors were more likely to contain actionable genetic alterations that made them suitable candidates for personalized treatments.

Biomarkers can detect earlier molecular and genetic changes associated with cancer development, which is crucial for improving patient outcomes. Biomarkers, especially those found in blood or other body fluids, provide non-invasive or minimally invasive options, reducing patient discomfort compared to endoscopy or biopsy. They also allow for real-time monitoring of disease progression and treatment response, facilitating personalized medicine. Moreover, biomarkers can help differentiate between benign and malignant lesions with higher sensitivity and specificity, overcoming limitations of imaging such as low resolution or operator dependency. Hence, some emerging trends in biomarkers for gastric cancer diagnostics are listed below.

Global Gastric Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global gastric cancer diagnostics market report based on product, disease type, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Reagents & Consumables
• Instruments
• Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
• Adenocarcinoma
• Gastric lymphoma
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Diagnostic Imaging
• Regional Outlook (Revenue in USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Disease Type
  • 1.2.3. End use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Disease type outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Gastric Cancer Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Gastric Cancer Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Segment Dashboard
• 4.3. Gastric Cancer Diagnostics Market: Product Movement Analysis
• 4.4. Gastric Cancer Diagnostics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.5. Gastric Cancer Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Reagents & consumables
  • 4.6.1. Reagents & consumables Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Instruments
  • 4.7.1. Instruments Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Gastric Cancer Diagnostics Market: Disease Type Estimates & Trend Analysis

• 5.1. Disease Type Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Gastric Cancer Diagnostics Market by Disease Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Adenocarcinoma
  • 5.5.1. Adenocarcinoma Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Gastric lymphoma
  • 5.6.1. Gastric Lymphoma Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Gastric Cancer Diagnostics Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Gastric Cancer Diagnostics Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Hospitals
  • 6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Diagnostic Laboratories
  • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Diagnostic Imaging
  • 6.7.1. Diagnostic Imaging Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Gastric Cancer Diagnostics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts, Trend Analysis, 2021 to 2033:
• 7.5. North America
  • 7.5.1. North America: SWOT Analysis
  • 7.5.2. U.S.
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/Reimbursement
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/Reimbursement
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/Reimbursement
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe: SWOT Analysis
  • 7.6.2. UK
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/Reimbursement
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/Reimbursement
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/Reimbursement
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/Reimbursement
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/Reimbursement
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Norway
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/Reimbursement
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/Reimbursement
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.9. Denmark
    • 7.6.9.1. Key country dynamics
    • 7.6.9.2. Regulatory framework/Reimbursement
    • 7.6.9.3. Competitive scenario
    • 7.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific: SWOT Analysis
  • 7.7.2. Japan
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/Reimbursement
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/Reimbursement
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/Reimbursement
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.5. Australia
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/Reimbursement
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.6. South Korea
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/Reimbursement
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Regulatory framework/Reimbursement
    • 7.7.7.3. Competitive scenario
    • 7.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America: SWOT Analysis
  • 7.8.2. Brazil
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/Reimbursement
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/Reimbursement
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. MEA
  • 7.9.1. MEA: SWOT Analysis
  • 7.9.2. South Africa
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/Reimbursement
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/Reimbursement
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/Reimbursement
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key country dynamics
    • 7.9.5.2. Regulatory framework
    • 7.9.5.3. Competitive scenario
    • 7.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. MiRXES Pte Ltd.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Agilent Technologies Inc
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Endofotonics Pte Ltd
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Bio-Rad Laboratories, Inc
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Hipro Biotechnology Co., Ltd
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Exact Sciences Corporation
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. QIAGEN
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Fulgent Genetics.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. F. Hoffmann-La Roche Ltd
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Abbott
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives